Pharmacological Characterization of a Selective Cox-2 Inhibitor Mf-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(Methylsulfonyl)phenyl)-2-(5h)-furanone], in Multiple Preclinical Species.
From: Department of Pharmacology, Molecular Biology and Biochemistry and Chemistry, Merck Frosst Center for Therapeutic Research, Merck Frosst, 16711 Trans-Canada Highway, Kirkland, Quebec, Canada.
European journal of pharmacology
- Publish Date: Apr 2007
- ISSN: 0014-2999
- Volume: 560
- Issue: 2-3
- Pages: 216-24
- Medium: Print
- Language: English
- Citation (JAMA): Rowland Steven E, Clark Patsy, Gordon Robert, et al. Pharmacological Characterization of a Selective Cox-2 Inhibitor Mf-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(Methylsulfonyl)phenyl)-2-(5h)-furanone], in Multiple Preclinical Species.. Eur. J. Pharmacol. Apr 2007;560:216-24
Abstract
Selective type 2 cyclooxygenase (COX-2) inhibitors are often used in preclinical studies without potency and selectivity data in the experimental species. To address this issue, we assessed a selective COX-2 inhibitor MF-tricyclic in four commonly used species, namely mice, rats, guinea pigs and rabbits, in the present study. In both the guinea pig and rabbit whole blood assay, the compound inhibited lipopolysaccharide (LPS)-induced PGE(2) production with an IC(50) (COX-2) of 0.6 and 2.8 microM, respectively. By comparison, the compound displayed a much weaker activity on clot-induced formation of thromboxane with an IC(50) (COX-1) of >10 microM (guinea pigs) and 23 microM (rabbits). In keeping with the in vitro potency data, the compound significantly inhibited interleukin-1 beta (IL-1beta) -induced PGE(2) formation in the rabbit synovium at plasma concentrations near the whole blood assay IC(50) for COX-2 but much lower than that for COX-1. MF-tricyclic was also potent and selective toward COX-2 in mice, inhibiting carrageenan-induced PGE(2) accumulation in the air pouch dose-dependently (ED(50)=0.5 mg/kg) without affecting stomach PGE(2) levels. In rats, MF-tricyclic was found to be effective in three standard in vivo assays utilized for assessing COX-2 inhibitors, namely, LPS-induced pyresis, carrageenan-induced paw edema and adjuvant-induced arthritis at the doses that did not inhibit stomach PGE(2) levels. Similar to that in rats, the compound displayed pharmacological efficacy in mice, guinea pigs and rabbits when tested in the LPS pyresis model. Our data reveal that MF-tricyclic has the desired biochemical and pharmacological properties for selective COX-2 inhibition in all four test species.
Mesh Headings (Keywords): Analgesics, Non-Narcotic, Animals, Anti-Inflammatory Agents, Non-Steroidal, Cyclooxygenase 2 Inhibitors, Dinoprostone, Dose-Response Relationship, Drug, Furans, Guinea Pigs, Interleukin-1beta, Lipopolysaccharides, Male, Mice, Mice, Inbred C57BL, Rabbits, Rats, Rats, Sprague-Dawley, Stomach
Check for Full Text / PubMed Unique Identifier (PMID): 17316604
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.